演題詳細
Symposium
基礎-臨床統合シンポジウム:iPS細胞の基礎研究から臨床応用まで
Integrated Symposium of Basic and Clinical Neuroscience:Inducued pluripotent stem (iPS) cells: from basic research to clinical application
開催日 | 2014/9/11 |
---|---|
時間 | 9:00 - 11:00 |
会場 | Room A(Main Hall) |
Chairperson(s) | 髙橋 良輔 / Ryosuke Takahashi (京都大学大学院医学研究科・臨床神経学 / Department of Neurology, Kyoto University Graduate School of Medicine, Japan) 岡野 栄之 |
神経変性疾患治療のためのiPS細胞の利用
The use of iPS cells toward the treatment of neurodegenerative diseases
- S1-A-1-2
- 井上 治久 / Haruhisa Inoue:1,2
- 1:京都大学iPS細胞研究所 増殖分化機構研究部門 幹細胞医学研究室 / Laboratory of Stem Cell Medicine, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan 2:独立行政法人科学技術振興機構, CREST / Japan Science and Technology Agency, CREST, Japan
The iPSC technology was established based on numerous findings by past and current scientists. Although the detailed mechanisms underlying the reprogramming process during iPSC generation are still being elucidated, the final products, which had previously been inaccessible, show promise for multiple purposes related to understanding disease mechanisms and treatment (Takahashi and Yamanaka, Development, 2013; Inoue et al., EMBO J., 2014).
In neurodegenerative diseases, selective neurons are vulnerable and degenerate. The greatest risk for these diseases is aging, and every person faces this unavoidable risk. For the coming aging society, prevention and control of these diseases will be research and social imperatives. Various research efforts up to now have been contributing to advancing their outcome, including neuropathological findings, discoveries of causative genes with functional analysis, and the generation of model animals. However, solving the diseases still remains, especially sporadic cases, the majority of the diseases. For understanding the diseases correctly, analysis of the neural cells of the patients has been required. Now, iPS cell technology is able to provide us with patient neural cells. Using these new materials, we are modeling the diseases, analyzing the disease markers for patient stratification, or cell transplantation research.
I will talk about our research for the use of iPS cells toward the treatment of neurodegenerative diseases.